WBDE(SZ:002082) Ge Long Hui A P P·2026-01-09 08:07Core Viewpoint - Wanbangde Pharmaceutical's Alzheimer's project has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica, indicating strong governmental support for innovative drug development in China [1][2] Group 1: Project Details - Wanbangde Pharmaceutical's subsidiary has received approval from the National Health Commission for its Alzheimer's disease project, which is part of a national major science and technology project aimed at developing innovative drugs for high-prevalence diseases [1] - The project focuses on the industrialization and clinical research of "Shisuanjianma Controlled Release Tablets," which is a key component of the clinical evaluation and innovative product research [1][2] Group 2: Market Context - There are nearly 17 million Alzheimer's disease and related dementia patients in China, highlighting a significant market need for effective treatments [2] - The national major science and technology project aims to encourage the development of urgently needed innovative drugs and establish a self-controlled national drug research and development system [1][2] Group 3: Clinical Research - The clinical research for Shisuanjianma Controlled Release Tablets is currently in a large-scale, high-quality Phase II/III trial, designed as a multi-center, randomized, double-blind study with placebo and positive control groups [2] - This study is notable for being the first in China to set dual primary efficacy endpoints and to use Aβ-PET imaging to observe amyloid protein deposition changes, which will help assess the drug's potential to delay disease progression [2] Group 4: Implications for the Company - The inclusion of Shisuanjianma Controlled Release Tablets in the national major science and technology project reflects recognition of its potential clinical value and Wanbangde Pharmaceutical's capabilities in drug development and clinical research [2] - Successful implementation of the research tasks is expected to enhance the company's technological level and market competitiveness in the field of neurodegenerative disease drug development, positively impacting the clinical development and industrialization of its pipeline drugs [2]